An open‐label study to explore the optimal design of CYP3A drug-drug interaction clinical trials in healthy Chinese people

• 主要な著者: Jingcheng Chen (著者), Jiangshuo Li (著者), Jingxuan Wu (著者), Yuqin Song (著者), Lijun Li (著者), Jianxiong Zhang (著者), Ruihua Dong (著者)
• フォーマット: 図書
• 出版事項: Wiley, 2024-08-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Abstract A drug-drug interaction (DDI) trial of cytochrome P450 3A (CYP3A) is a necessary part of early‐phase trials of drugs mainly metabolized by this enzyme, but CYP3A DDI clinical trials do not have a standard design, especially for Chinese people. We aimed to offer specific recommendations for...